1. Home
  2. COHN vs MCRB Comparison

COHN vs MCRB Comparison

Compare COHN & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Company Inc.

COHN

Cohen & Company Inc.

HOLD

Current Price

$10.08

Market Cap

38.7M

Sector

Finance

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$3.92

Market Cap

41.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHN
MCRB
Founded
1999
2010
Country
United States
United States
Employees
N/A
66
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
41.2M
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
COHN
MCRB
Price
$10.08
$3.92
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
21.9K
47.4K
Earning Date
05-01-2026
05-11-2026
Dividend Yield
4.35%
N/A
EPS Growth
5537.50
N/A
EPS
1.36
N/A
Revenue
$275,564,000.00
$789,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.46
N/A
Revenue Growth
246.19
N/A
52 Week Low
$9.19
$3.90
52 Week High
$32.60
$29.98

Technical Indicators

Market Signals
Indicator
COHN
MCRB
Relative Strength Index (RSI) 33.23 34.20
Support Level N/A N/A
Resistance Level $11.56 $5.80
Average True Range (ATR) 0.40 0.34
MACD -0.04 -0.11
Stochastic Oscillator 16.22 7.80

Price Performance

Historical Comparison
COHN
MCRB

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Share on Social Networks: